ROCKVILLE, Md., Aug. 26,
2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a
US-based, global, clinical-stage biotech company, exclusively
focused on the development of highly differentiated immunotherapies
for the treatment of cancer, today announced that management will
present at the H.C. Wainwright 26th Annual Global Investment
Conference on September 10, 2024.
H.C. Wainwright 26th Annual Global Investment
Conference
|
Presentation
Time
|
Tuesday, September
10 at 5:00 PM ET
|
|
Presenters
|
Sean Fu, PhD, Interim
Chief Executive Officer (CEO)
Phillip Dennis, MD,
PhD, Chief Medical Officer (CMO)
|
|
Webcast link
|
Here
|
|
Meetings
|
One-on-one and small
group meetings: September 9 – 10, 2024
|
|
Management
Participants
|
Sean Fu, PhD, Interim
CEO
Joe Skelton, Chief
Financial Officer (CFO)
Phillip Dennis, MD,
PhD, CMO
Tyler Ehler, Senior
Director, Investor Relations
|
The webcast will also be available under "Event Calendar"
on I-Mab's IR website
at https://ir.i-mabbiopharma.com/
For more information, please contact your H.C. Wainwright
representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based,
global, clinical-stage biotech company, exclusively focused on the
development of highly differentiated immunotherapies for the
treatment of cancer. I-Mab has established operations in
Rockville, Maryland. For more
information, please visit https://www.i-mabbiopharma.com and follow
us on LinkedIn and X.
For more information, please
contact:
Tyler
Ehler
Senior Director, Investor
Relations
IR@imabbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-hc-wainwright-26th-annual-global-investment-conference-302230144.html
SOURCE I-Mab Biopharma